Do female sex hormones initiate breast cancer? A review of the evidence

Climacteric

Volumn 7, Issue 2, 2004, Pages 120-128

  Wren, B G ^a,b  

^a Sydney Menopause Centre   (Australia)

^b Eastpoint Tower ^*  (Australia)

Author keywords

Breast cancer; Cell mutations; Estrogen; Progestogens

Indexed keywords

CARCINOGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYCLIN DEPENDENT KINASE; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SEX HORMONE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER RISK; CELL ACTIVITY; CELL GROWTH; CYTOLOGY; DEATH; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; METASTASIS; MITOGENESIS; MITOSIS; MUTATION; ONCOGENE; PERIPHERAL CIRCULATION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; GONADAL STEROID HORMONES; HUMANS;

EID: 3242665918     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130410001713797     Document Type: Review

References (62)

1. US National Institute of Environmental Health Science - Biennial Report of Carcinogens, December 2002, 10th Edition. US Congress Reports
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59
3. Schairer C, Lubin J, Troisis R, et al. Menopausal estrogen and estrogen/progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485-91
4. Ross RK, Paganini-Hill A, Wan PC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32
5. Million Women Collaborators. Breast cancer and hormone replacement in the Million Women Study. Lancet 2003;362:419-27
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33
7. Phillips KA, Glendon G, Knight J. Putting the risk of breast cancer in perspective. N Engl J Med 1999;340:141-4
8. Henderson IC. Risk factors for breast cancer development. Cancer 1993;Suppl 71:2127-40
9. Kricker A, Jelf P. Risks of breast cancer by age: Cancer Series No. 6. Breast cancer in Australian women 1921-1994. Australian Institute of Health and Welfare National Health and Medical Research Council. National Breast Cancer Centre, Canberra, 1996:13
10. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13
11. Australian Institute of Health and Welfare. Australian Association of Cancer Registries and NHMRC National Breast Cancer Centre 1999: Breast Cancer in Australian Women 1982-1996, Canberra AIHW (Cancer Series)
12. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47
13. MacMahon B, Cole P, Lim M, et al. Age at first birth and breast cancer risk. Bull WHO 1970;43:209-21
14. Layde PM, Webster LA, Baugham AL, et al. The independent association of parity, age at first full term pregnancy and duration of breast feeding with the risk of breast cancer. J Clin Epidemiol 1989;42:963-73
15. Romieu I, Berlin JA, Colditz G. Oral contraception and breast cancer: review and metaanalysis. Cancer 1990;66:2253-63
16. Malone KE, Darling JR, Weiss MS. Oral contraception and breast cancer risk. Epidemiol Rev 1993;15:80-97
17. Thomas DB. Oral contraceptives and breast cancer: review of the epidemiological literature. Contraception 1991;1:973-82
18. UK National Case-Control Study Group. Oral contraceptive and breast cancer risk. Epidemiol Rev 1993;15:597-641
19. Yeates D. Report: MRC/FPA Study of Contraception and Women's Health. Oxford University, Unit of Health Care Epidemiology, Dept of Public Health, Oxford, 2003:1-2
20. Blankenstein MA, Syzmczak J, Daroszewski J, et al. Estrogen in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncogenic reasons. Gynecol Endocrinol 1992;6:13
21. Pasqualini JR, Chetrite G. Control of estrone sulfatase activity in human breast cancer cells: effect of tibolone and its metabolites. Gynecol Endocrinol 1996;11:69-75
22. Bulun SE, Price TM, Aitken J, et al. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993;77:1622-8
23. Rose C, Mouridsen HT. Endocrine management of advanced breast cancer. Horm Rev 1989;32(Suppl 1):189-97
24. Ingle JN, Ahman DL, Green SJ, et al. Randomised clinical trial of megestrol acetate versus tamoxifen in perimenopausal or castrated women with advanced breast cancer. Am J Clin Oncol (CCT) 1982;5:155-6
25. Persson L, Yuen J, Bergkvist I, et al. Combined oestrogen/progestogen replacement therapy and breast cancer risk. Lancet 1992;340:1044-6
26. Weiss LK, Burkman RT, Cushing-Huagen KL. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-58
27. Ng EH, Gao F, Ji CY, et al. Risk factors for breast carcinoma in Singaporean Chinese women: the role of central obesity. Cancer 1997;80:725-31
28. Moorman PG, Kuwabara H, Millikan RC, Newman B. Menopause hormones and breast cancer in a biracial population. Am J Pub Health 2000;90:966-71
29. Bush T, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508
30. Lando JF, Heck KE, Brett KM. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 1999;17:176-80
31. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
32. Creasman WT, Hoel D, DiSaia PJ. WHI: now that the dust has settled. Am J Obstet Gynecol 2003;189:621-6
33. Fedi P, Tronick SR, Aaronson SA. Growth factors. In Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR, eds. Cancer Medicine. Baltimore: Williams and Wilkins, 1997:41-4
34. Hunter T. Oncoprotein networks. Cell 1997;898:333-46
35. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30
36. Foley KP, Eisenman RN. Two MAD tails: what the recent knockouts of Mad 1 and M x 2 tell us about MYC/MAX/MAD networks. Biochem Biophys Acta 1999;1423:M37-47
37. Moses HL, Yang EY, Pietenpol JA. TGFβ stimulation and inhibition of cell cycle arrest. Nature 1994;371:257-61
38. Hannan GJ, Beach B. P15 INK 48 is a potential effector of TGFβ induced cell cycle arrest. Nature 1994;371:257-61
39. Musgrove EA, Sutherland RL. Steroidal control of cell proliferation in the breast and breast cancer. In Wren B G, ed. Progress in the Management of the Menopause. Carnforth, UK: Parthenon, 1996:194-202
40. Musgrove EA, Sutherland RL. Cell cycle control by steroid hormones. In Parker M G, ed. Seminars in Cancer Biology. London: Academic Press, 1994;5:381-98
41. Musgrove EA, Hui R, Sweeney KJE, et al. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 1996;1:153-62
42. Groshong SD, Owen GI, Grimson B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of cyclin-dependent kinase inhibitors P21 and P27KIP 11. Mol Endocrinol 1991;11:1593-607
43. Musgrove EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression whilst increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 1991;11:5032-43
44. Ashkenazi A, Dixit VM. Apoptosis by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60
45. Giancotti FG, Ruoslahti E. Integrin signalling. Science 1999;285:1028-32
46. Hayflick L. Mortality and immortality at the cellular level: a review. Biochemistry 1997;62:1180-90
47. Bryan TM, Cech TR.Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol 1999;11:318
48. Bouck M, Stellmack V, Hsu SC. How tumours become angiogenic. Adv Cancer Res 1996;69:135-74
49. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:362-4
50. Kim KJ, Li B, Winer J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
51. Sporn MB. The war on cancer. Lancet 1996;347:1377-81
52. Christofori G, Semb H. The role of the cell adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999;24:73-6
53. Musgrove EA, Lee CSL, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci 1994;91:8022-6
54. Sutherland RL, Watts CKW, Musgrove EA. Cell cycle control by steroid hormones in breast cancer: implications for endocrine resistance. Endocrine Related Cancer 1995;2:87-96
55. Pasqualini JR, Chetrite G. Control of oestrone sulfatase activity in human breast cancer cells: effect of tibolone and its metabolites. Gynecol Endocrinol 1996;11:69-75
56. Geisler J, King N, Dowsett M, et al. Influence of anastrazole (Arimidex), a selective non-steroidal aromatase inhibitor on in-vivo aromatisation and plasma oestrogen level in post menopausal women with breast cancer. Br J Cancer 1996;74:1286-91
57. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106:1-21
58. Graham JD, Clarke CL. Physiological action of progesterone in target tissue. Endocrine Rev 1997;18:502-18
59. Russo J, Russo IH. Role of hormones in human breast development: the menopausal breast. In Wren BG , ed. Progress in the Management of the Menopause. Proceedings of the 8th International Congress on the Menopause. Carnforth, UK: Parthenon, 1996:184-93
60. Hankinson S, Willett WC, Manson JE, et al. Plasma sex steroid levels and risk of breast cancer in post menopausal women. J Natl Cancer Inst 1998;90:1292-7
61. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous oestrogens and breast cancer in post menopausal women. J Natl Cancer Inst 1995;87:190-7
62. Plu-Bureau G, Le MG, Sitruk-Ware R, et al. Progestogen use and decreased risk of breast cancer in a cohort study of pre-menopausal women with benign breast disease. Br J Cancer 1995;70:270-7